PTO-1449 REPRODUCED	ATTORNEY DOCK 3474.1001-011	ET NO.	APPLICATION 10/791,223	N NO.
SECOND SUPPLEMENTAL INFORMATION OF PEDISCLOSURE STATEMENT OF IN AN APPLICATION	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
April 25, 2007  (Use several sheets if necessary)	EXAMINER Brian S. Kwon	3953	RMATION NO.	GROUP 1614

		0.5	. PATENT DOCUMENT	
AM IER I-	REF.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/B.K	/ <sup>A27</sup>	6,104,956	08-15-2000	Naritoku et al.
		·		
			·	
_				
	ļ			
	-			
	<u>.</u>			
<del></del>	-			
	-			
	-			
	721384			

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED	07/19/2007	•	

DISCLOSURE STATEMENT  NAN APPLICATION  FIRST NAMED INVENTOR March 2, 2004  March 2, 2004  EXAMINER CONFIRMATION NO. GRO	PTO-1449 REPRODUCED  CATODA SEASENITE A LANGODAM A TAOM	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATIO 10/791,223	APPLICATION NO. 0/791,223	
March 5, 2007	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT OF EN AN APPLICATION		VENTOR			
(Use sected sheets if necessary)	MAR 0 8 2007	EXAMINER Unknown	3953	RMATION NO.	GROUP 1614	

<u> </u>	<u> </u>	
	PADE	CHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  [Chertkow, H., "Mild Cognitive Impairment," Curr. Opin. in Neurol. 15:401-407 (2002).
/B.K./	C269	Chertkow, H., "Mild Cognitive Impairment," Curr. Opin. in Neurol. 15:401-407 (2002).
	C270	Clarke, A., "A New Formulation of Selegiline: Improved Bioavailability and Selectivity for MAO-B Inhibition," J. Neural. Transm. 110:1241-1255 (2003).
	C271	Gauthier, S., et al., "Mild Cognitive Impairment," The Lancet 367:1262-1270 (2006).
	C272	Grundman, M., et al., "Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials," Arch. Neurol. 61:59-66 (2004).
	C273	Halgren, E., et al., "Human Hippocampal Formation EEG Desynchronizes During Attentiveness and Movement," Electroencephalography and Clinical Neurophysiology 44:778-781 (1978).
	C274	Lynch, G., et al., "The Nature and Causes of Hippocampal Long-term Potentiation," Progress in Brain Research 83:233-250 (1990).
	C275	Mild Cognitive Impairment. Alzheimer's Society Information Sheet [online], March 2005. Retrieved from the Internet <url: http:="" www.alzheimers.org.uk="">.</url:>
	C276	Mild Cognitive Impairment-Alzheimer's Disease Part XVI [online], November 2006 [retrieved on 2007-01-24]. Retrieved from the Internet <url:http: www.therubins.com="">.</url:http:>
	C277	Meeker, J.S. and Reynolds, P.C., "Postmortem Tissue Methamphetamine Concentrations Following Selegiline Administration," J. of Analytical Toxicology 14:330-331 (1990).
	C278	Nickel, B., et al., "Evaluation of Physical Dependence Liability of <i>l</i> -deprenyl (Selegiline) in Animals," Clinical Pharmacology & Theraptutics, 56(6):757-767 (1994).
	C279	Petersen, R.C., et al., "Current Concepts in Mild Cognitive Impairment," Arch Neurol. 58:1985-1992 (2001).
	C280	Uchida, S., et al., "Cortical Oscillations in Human Medial Temporal Lobe During Wakefulness and All-night Sleep," Brain Research 891:7-19 (2001).
	C281	Yasar, S., et al., "Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(-)-Deprenyl]," The Journal of Pharmacology and Experimental Therapeutics 317(1):387-394 (2006).
$\bigvee$	C282	Kwon, Y. S., et al., "Selegiline Potentiates the Effects of Egb 761 in Response to Ischemic Brain Injury," Neurochemistry International 45:157-170 (2004).

EXAMINER /	Brian-Yong Kwon/	DATE CONSIDERED	07/19/2007	
		i e		

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-011  FIRST NAMED INVENTOR Mel H. Epstein		APPLICATION NO. 10/791,223 FILING DATE March 2, 2004	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION  March 5, 2007				
	EXAMINER Unknown	CONFI 3953	RMATION NO.	GROUP 1614
(Use several sheets if necessary)				1

/B.K./	Semkova, I., et al., "Selegiline Enhances NGF Synbthesis and Protects Central Nervous System Neurons from Excitotoxic and Ischemic Damage," European Journal of Pharmacology 315:19-30 (1996).
/B.K./ <sup>C284</sup>	Sivenius, J., et al., "Selegiline Treatment Facilitates Recovery After Stroke,"  Neurorehabilitation and Neural Repair 15:183-190 (2001).

DATE CONSIDERED **EXAMINER** /Brian-Yong Kwon/ 07/19/2007

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-011  FIRST NAMED INVENTOR Mel H. Epstein		APPLICATION NO. 10/791,223 FILING DATE March 2, 2004	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION				
June 4, 2007  (Use several sheets if necess	EXAMINER Brian S. Kwon	CONFII 3953	RMATION,NO.	GROUP 1614

	•	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
/B.K.	C285	Peterson, D. W., and Sparber, S. B., "Differential Actions of d- and l-amphetamine on the Metabolism of 3H-norepinephrine in Rat Brain," <i>Pharmacol. Biochem. Behav.</i> , 4(5): Abstract (1976).
		·
		·

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 07/19/2007